相关实验视频
Updated: Jul 26, 2025

10:18
In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium
Published on: May 6, 2018
9.4K
通过体质基因转移进行的焦点抗凝剂:预防心血管血栓性中风
Megha Kadian1, Cindy Y Kok2, Dhanya Ravindran2
1The Centre for Heart Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine, The University of Queensland, St Lucia, Qld, Australia.
Heart, lung & circulation
|June 14, 2023
概括
心血管栓塞性中风 (CS) 是缺血性中风 (IS) 的主要原因之一. 基因疗法提供了一种针对血栓形成原因的新方法,解决了高风险患者目前抗凝治疗方法的局限性.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
背景情况:
- 心血管栓塞性中风 (CS),通常源于左心房附属体 (LAA),是缺血性中风 (IS) 的主要原因.
- 目前的治疗方法,如全身抗凝药,不是个性化的,并且有禁忌,使高风险患者容易受到伤害.
- 耳前尾闭塞装置可以减轻LAA-血栓的风险,但它们昂贵,侵入性,并且没有解决潜在的原因.
研究的目的:
- 探索基于病毒载体的基因疗法在治疗心血管血栓性中风 (CS) 的潜力.
- 为了解决有关腺相关病毒 (AAV) 基因疗法对CS等血栓性疾病的研究上的差距.
- 研究基因疗法向促进CS血栓形成的分子途径的能力.
主要方法:
- 关于当前CS治疗和基因疗法在血液静止疾病中的应用的文献综述.
- 分析基因相关病毒 (AAV) 载体对向基因传递的潜力.
- 探索基因疗法解决CS分子病因学的能力.
主要成果:
- 系统性抗凝药和基于设备的疗法对CS管理有局限性.
- 腺相关病毒 (AAV) 基因疗法在其他静血性疾病 (如血友病) 中取得了成功.
- 基因疗法通过解决血栓形成机制,为本地化,向性治疗CS提供了一种新的策略.
结论:
- 基因疗法作为心血管栓塞性中风 (CS) 的个性化和有针对性的治疗方法具有前景.
- 对基于AAV的CS基因疗法的进一步研究是有必要的,以解决未满足的临床需求.
- 向血栓形成的分子基础为CS治疗提供了潜在的范式转变.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
767
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
767
Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Gene Therapy
25.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.6K
Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K

